[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100622111":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":24,"centralContacts":29,"locations":12,"responsibleParty":40,"collaborators":12,"id":42,"slug":43,"hasResults":44,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":44,"sex":50,"minAge":51,"maxAge":12,"enrollmentInfo":52,"targetDuration":12,"studyType":55,"phases":56,"briefSummary":58,"conditions":59,"keywords":61,"overallStatus":65,"whyStopped":12,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":12},{"fullName":5,"class":6},"University Hospital, Grenoble","OTHER",[8,13],{"label":9,"type":10,"description":11,"interventionNames":12},"hospital based follow-up","NO_INTERVENTION","The patient must arrive with a full bladder (a minimum volume of 150 mL, including both the voided volume and the post-void residual), refrain from voiding until urinating into the uroflowmeter, have completed their bladder diary at home beforehand (measuring with a graduated container over 3 days and 3 nights), have filled out the EQ-5D-5L (quality of life), USP (urinary symptoms), and PGI (post-treatment global impression of improvement) questionnaires, and bring them along",null,{"label":14,"type":15,"description":16,"interventionNames":17},"home based follow-up group","EXPERIMENTAL","A nurse from the provider will bring the equipment required for the different measurements (Homeflow®) and explain its use to the patient. The nurse will also give the patient the EQ-5D-5L (quality of life), USP (urinary symptoms), and PGI (post-treatment global impression of improvement) questionnaires in paper format. A first assessment of the PVR may already be performed. The nurse will return to collect the equipment and questionnaires and to perform a PVR measurement 72 hours later. The recorded data are transmitted directly to the physician, who can view them on their computer (a dedicated secure application provided with the Homeflow solution) and export them in PDF format to add them to the patient's file.\"",[18],"Other: home care",[20],{"type":6,"name":21,"description":22,"armGroupLabels":23,"otherNames":12},"home care","6-week follow-up visit: At home (The service provider will bring the necessary equipment for the various measurements and the questionnaires, and will explain their use to the patient. The provider will return to collect the equipment and perform a post-void residual (PVR) measurement 72 hours later.)",[14],[25],{"name":26,"affiliation":27,"role":28},"caroline ct thuillier, physician","university grenoble hospital","PRINCIPAL_INVESTIGATOR",[30,36],{"name":31,"role":32,"phone":33,"phoneExt":34,"email":35},"caroline CT thuillier, physician","CONTACT","0476767453","+33","cthuillier@chu-grenoble.fr",{"name":37,"role":32,"phone":38,"phoneExt":34,"email":39},"assilah AB BOUZIT, study co","0476767971","abouzit@chu-grenoble.fr",{"type":41,"investigatorFullName":12,"investigatorTitle":12,"investigatorAffiliation":12,"oldNameTitle":12,"oldOrganization":12},"SPONSOR","100622111","bladder-overactivity-and-post-botulinum-toxin-telemonitoring-100622111",false,"NCT07379372","Bladder Overactivity and Post-Botulinum Toxin Telemonitoring","Bladder Overactivity and Post-Botulinum Toxin Telemonitoring: a Randomized, Controlled, Superiority Trial","VESIC@HOME","Inclusion Criteria:\n\n* Patient with a neurogenic bladder or idiopathic overactive bladder.\n* Patient treated with intradetrusor botulinum toxin injection as part of their usual care, whether performing spontaneous voiding or self-catheterization.\n* Patient whose residence allows a home visit by a service provider within the area covered by the AGIR à dom group.\n* Patient affiliated with the social security system.\n* Patient willing to provide informed consent\n\nExclusion Criteria:\n\n* Persons covered under Articles L1121-5 to L1121-8 of the French Public Health Code (CSP), corresponding to all protected persons: pregnant or postpartum women, breastfeeding mothers, individuals deprived of liberty by judicial or administrative decision, persons receiving psychiatric care under Articles L. 3212-1 and L. 3213-1 who are not covered by the provisions of Article L. 1121-8, individuals admitted to a healthcare or social facility for purposes other than research, minors, persons under legal protection, or individuals unable to give consent.\n* Staff members with a hierarchical relationship with the principal investigator.","ALL","18 Years",{"count":53,"type":54},112,"ESTIMATED","INTERVENTIONAL",[57],"NA","Prospective, randomized, controlled, single-center study to compare the feasibility of home monitoring for patients receiving intradetrusor botulinum toxin injections with that of the usual hospital-based follow-up.",[60],"Overactive Bladder",[62,63,64],"urinary incontinence","botulinum toxin","connected urinary incontinence","NOT_YET_RECRUITING","2026-01-26",{"date":68,"type":69},"2026-01-30","ACTUAL",{"date":71,"type":54},"2026-03-02",{"date":73,"type":54},"2031-03-02",{"name":5,"class":6}]